TO THE EDITOR
Metastatic melanoma patients harboring a BRAF gene mutation on codon 600 can be treated with targeted therapies (Flaherty, 2012) . Depending on the content of tumor cells and on the analytical sensitivity, BRAF mutations are found in 50-70% of metastatic melanoma patients (Davies et al., 2002) . Around 80% display a valineto-glutamic acid substitution (V600E) and B16% harbor a valine-tolysine substitution (V600K) causing constitutive kinase activation (Wan et al., 2004; Rubinstein et al., 2010) . BRAF V600E mutation analysis is currently performed in daily clinical practice on tissue samples using various molecular biology technologies. Moreover, the detection of the BRAF V600E mutation in blood samples from melanoma patients in the context of translational research and clinical trials has been described (Board et al., 2009; Sakaizawa et al., 2012) . Metastatic dissemination correlates with the presence of circulating tumor cells (CTCs) detected in blood samples (Paterlini-Brechot et al., 2011; Alix-Panabières et al., 2012) . The detection of circulating melanoma tumor cells (CMCs) can be performed using different technologies, in particular by the isolation by size of epithelial tumor cells (ISET) method, a direct method that allows cytopathological analysis of CMCs (De Giorgi et al, 2010) . Moreover, ancillary methods for CTC characterization can be performed on cells isolated by ISET (De Giorgi et al., 2010; Ilie et al., 2012) . Recent studies highlighted the value of immunohistochemistry (IHC) using the VE1 antibody for the detection of the BRAF V600E mutation in melanoma (Capper et al., 2012 Table S2 ). Homogenous intracytoplasmic staining without associated nuclear staining was demonstrated in melanoma cells only (Figure 1 ). Among the tumors negative for the BRAF mutation by pyrosequencing, none had positive VE1 immunostaining (Supplementary Table S2 ; Figure 1 ). An excellent concordance was found between these two methods (Supplementary Table S2 (Figure 1) . Control immunostaining on CMCs using anti-CD45 was negative (not shown).
This study shows that CMCs isolated by ISET can be used to detect the BRAF V600E mutation in patients with advanced melanoma by using the VE1 antibody. We demonstrated that this noninvasive approach is highly sensitive and relatively specific for the detection of BRAF V600E in CMCs, having high level of concordance with results in tissue samples. In comparison with other approaches used for the detection of BRAF V600E from blood samples, ISET allows cytopathological detection of CMCs before the analysis for a mutation, affording correlation of cytomorphological and ICC data and avoiding interpretation bias (Paterlini-Brechot et al., 2007) . Moreover, ISET is a rapid and low-cost method that can easily be repeated, thereby allowing the monitoring of CMC detection in patients on targeted therapy. The use of ICC for the detection of the BRAF V600E mutation on CMCs has advantages, but also a few potential drawbacks. Interestingly, eight patients included in the present series showed CMCs positively stained by ICC using the VE1 antibody, whereas BRAF V600E was not found in the corresponding tumor tissue samples. As molecular heterogeneity is a common event in tumors, it is possible that the tissue sample used for both pyrosequencing and IHC analysis may not harbor the BRAF V600E mutation (Longo, 2012) . In these cases, BRAF
V600E
-mutated CMCs derived from other parts of the tumor would have invaded the blood stream, initiating metastatic dissemination. Second, even if pyrosequencing is a sensitive technology (B5%), the presence of a small amount of mutated cells in the tissue sample may give a false negative result (Gonzalez de Castro et al., 2012) . It has been described previously that VE1 immunostaining may be useful for the detection of smaller amounts of BRAF V600E -mutated cells in tissue sections (Capper et al., 2012) . The hypothesis of a false positive ICC result on CMCs can be reasonably eliminated, as negative controls made in parallel on CMCs isolated by ISET did not show any staining. Future developments on the investigation of the BRAF V600E mutation in CMCs isolated by ISET, both by ICC and DNA sequencing, should add more information to this issue. For now, the low number of detected CMCs (from two to eight CMCs) in these eight patients did not allow us to obtain conclusive results by pyrosequencing performed on extracted DNA from CMCs. Larger studies are now needed to determine whether the detection of BRAF V600E in CMCs using VE1 immunostaining could allow the selection of patients for a targeted therapy, despite the absence of detection in tissue sample. In conclusion, CMCs can be detected by ISET in patients with advanced melanoma, and can be analyzed by using ICC with the VE1 antibody for the identification of the BRAF V600E mutation in melanoma cells. This approach is noninvasive, rapid, very sensitive, and specific, and opens new options for taking care of metastatic melanoma patients in the era of innovative targeted treatments.
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